Having raised the full-year sales guidance for Caplyta (lumateperone) a week ago, Intra-Cellular Therapeutics has reported ...

Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants ...

Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...

The ROS1 inhibitor market for NSCLC, valued at around $290 million in 2023 across the USA, Europe, and Japan, is set for growth with new-generation therapies targeting resistance mutations.

Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with ...

University of Michigan researchers have added a new dimension to the mathematics used to predict the outcomes of all manner of competitions, including sports, games and social hierarchies in both ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

VANCOUVER, British Columbia and ROAD TOWN, British Virgin Islands, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bluestone Resources Inc.

Addition of the antipsychotic lumateperone (Caplyta) to an existing antidepressant improved symptoms of depression in a ...

Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on ITCI stock, giving a Buy rating today. Jason Gerberry ...

Cantor Fitzgerald raised the firm’s price target on Intra-Cellular (ITCI) to $135 from $130 and keeps an Overweight rating on the shares.

这一扩张是公司抓住双相抑郁症（BPD）市场机遇策略的一部分。Intra-Cellular还首次对其旗舰产品Caplyta进行了预测，预计未来十年销售额将超过50亿美元。这一估计假设公司在BPD和重度抑郁症（MDD）市场占据领先份额，并预期净价格会有所提升。 高盛预计 ...